ArticleCureus2025
Sequential Folliculitis, Paraspinal Myositis, and Septic Arthritis Due to Hematogenous Staphylococcus aureus Infection in a Patient Receiving Adalimumab Therapy.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Skin infections are a well-recognized source of bacteremia and can serve as foci for hematogenous spread leading to sepsis, septic arthritis, or osteomyelitis. Immunosuppressive therapies, particularly tumor necrosis factor alpha (TNF-α) inhibitors such as adalimumab, predispose patients to severe infections and are associated with increased infectious morbidity and mortality. These agents impair innate immune signaling and may attenuate the clinical manifestations of infection. Specifically, TNF-α blockade disrupts downstream interleukin-1β (IL-1β) and interleukin-6 (IL-6) pathways that mediate leukocyte recruitment and the febrile response. Consequently, patients receiving TNF-α inhibitors may present with bacteremia or early sepsis in the absence of typical findings such as fever or leukocytosis, potentially delaying diagnosis and treatment. We report a middle-aged Caucasian male patient receiving adalimumab therapy who initially presented to the emergency department with presumed paraspinal muscle strain and degenerative spondylosis. Magnetic resonance imaging (MRI) was interpreted as consistent with muscular strain and degenerative spondylosis. Subsequent orthopedic evaluation revealed a septic-appearing left knee, with synovial and blood cultures positive for methicillin-sensitive
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.